Patent US2308083A successfully refreshed from Google Patents.
Patent US4303645A successfully refreshed from Google Patents.
US4303645A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Modified living canine parvovirus vaccine
Assignee: Cornell Research Foundation Inc
•
Filing: 1980-04-18
•
Granted: 1981-12-01
•
Expires: 2000-04-18
Abstract
Abstract A safe, efficacious vaccine for protecting dogs against infection caused by canine parvovirus is produced by prolonged serial passages in non-oncogenic cell lines. One embodiment includes the use of sub-optimal temperatures (below that normal for the dog) during passaging.
Inventors
- 👤 Leland E. Carmichael
- 👤 Max J. G. Appel
- 👤 Douglas D. McGregor
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 22:42
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61K; A61K39/00; C12; C12N; C12N2750/00; C12N2750/00011; C12N2750/14011; C12N2750/14311; C12N2750/14322; Y; Y10; Y10S; Y10S424/00; Y10S424/818
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
63 words
A method of protecting dogs from infection caused by canine parvovirus comprising inoculating an animal with modified living canine parvovirus vaccine (CPV) prepared in accordance with a procedure which comprises taking a seed of a virulent CPV strain and serially passaging the strain in non-oncogenic cell cultures at a sub-optimal temperature at which CPV growth occurs until a non-virulent, immunizing virus is produced.
Claim 2
Independent Claim
63 words
A method of protecting dogs from infection caused by canine parvovirus comprising inoculating an animal with modified living canine parvovirus vaccine (CPV) prepared in accordance with a procedure which comprises taking a seed of a virulent CPV strain and serially passaging the strain in non-oncogenic cell cultures at a sub-optimal temperature at which CPV growth occurs until a non-virulent, immunizing virus is produced.
Claim 3
Dependent Claim
15 words
The method of claim 1 in which the serial passaging comprises at least 80 passages.
Claim 4
Dependent Claim
13 words
The method of claim 2 in which the serial passaging comprises 108 passages.
Claim 5
Dependent Claim
14 words
The method of claim 1 in which the passage temperature is approximately 33° C.
Claim 6
Dependent Claim
45 words
The method of claim 1 in which the nononcogenic cell culture consists of a medium selected from the group consisting of MDCK cell line (CCL-34), canine kidney cells, mink lung cells, bovine fetal spleen cells, bovine testicular cells, feline lung cells, or feline renal cells.
Claim 7
Dependent Claim
13 words
The method of claim 1 in which the virulent CPV strain is CPV-916.
Claim 8
Dependent Claim
56 words
A modified live vaccine for protecting dogs against infection caused by canine parvovirus produced by a process comprising the steps of taking a seed of a virulent CPV strain and serially passaging the strain in non-oncogenic cell cultures at a sub-optimal temperature at which CPV growth occurs with periodic tests until a non-virulent strain is produced.
Claim 9
Dependent Claim
56 words
A modified live vaccine for protecting dogs against infection caused by canine parvovirus produced by a process comprising the steps of taking a seed of a virulent CPV strain and serially passaging the strain in non-oncogenic cell cultures at a sub-optimal temperature at which CPV growth occurs with periodic tests until a non-virulent strain is produced.
Claim 10
Dependent Claim
15 words
The vaccine of claim 7 in which the serial passaging comprising at least 80 passages.
Claim 11
Dependent Claim
13 words
The vaccine of claim 8 in which the serial passaging comprises 108 passages.
Claim 12
Dependent Claim
14 words
The vaccine of claim 7 in which the passage temperature is approximately 33° C.
Claim 13
Dependent Claim
45 words
The vaccine of claim 7 in which the non-oncogenic cell culture consists of a medium selected from the group consisting of MDCK cell line (CCL-34), canine kidney cells, mink lung cells, bovine fetal spleen cells, bovine testicular cells, feline lung cells, or feline renal cells.
Claim 14
Dependent Claim
13 words
The vaccine of claim 7 in which the virulent CPV strain is CPV-916.
Claim 15
Independent Claim
58 words
The method of producing a modified live vaccine for protecting dogs against canine parvovirus comprising the steps of: a. Starting with a seed of virulent CPV; b. Serially passaging the virus in non-oncogenic cell cultures at a sub-optimal temperature at which CPV growth occurs; c. Periodically testing the passaged virus for virulence until a non-virulent virus is produced.
Claim 16
Independent Claim
58 words
The method of producing a modified live vaccine for protecting dogs against canine parvovirus comprising the steps of: a. Starting with a seed of virulent CPV; b. Serially passaging the virus in non-oncogenic cell cultures at a sub-optimal temperature at which CPV growth occurs; c. Periodically testing the passaged virus for virulence until a non-virulent virus is produced.
Claim 17
Dependent Claim
15 words
The method of claim 13 in which the serial passaging comprises at least 80 passages.
Claim 18
Dependent Claim
13 words
The method of claim 14 in which the serial passaging comprises 108 passages.
Claim 19
Dependent Claim
14 words
The method of claim 13 in which the passage temperature is approximately 33° C.
Claim 20
Dependent Claim
45 words
The method of claim 13 in which the nononcogenic cell culture consists of a medium selected from the group consisting of MDCK cell line (CCL-34), canine kidney cells, mink lung cells, bovine fetal spleen cells, bovine testicular cells, feline lung cells, or feline renal cells.
Claim 21
Dependent Claim
13 words
The method of claim 13 in which the virulent CPV strain is CPV-916.
References Cited (Backward Citations)
US2136131A
Cited
US2271819A
Cited
US2271818A
Cited
US3133861A
Cited
DE1174016B
Cited
US3293130A
Cited
US3577525A
Cited
US3346456A
Cited
US3465077A
Cited
FR1426195A
Cited
US3285817A
Cited
US3520972A
Cited
US3562387A
Cited
GB1286250A
Cited
US3709782A
Cited
US3733401A
Cited
US3869547A
Cited
US3892627A
Cited
US3944469A
Cited
US4004974A
Cited
US4211843A
Cited
US4193991A
Cited
US4213965A
Cited
US4193990A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-11-30 | 1985-06-01 | 1985-12-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-11-30 | 1989-06-01 | 1989-12-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-11-30 | 1993-06-01 | 1993-12-01 | $7700.00 | Window Closed / Lapsed |